pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
D9604C00001
Phase 3 · small molecule · Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.
D9604C00001 for Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Internal code D9604C00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca AB
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.
- Status
- active
- Trials
- 1